Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-02-28
2011-11-22
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S304400
Reexamination Certificate
active
08063089
ABSTRACT:
Nucleophosmin inhibitors are disclosed which inhibit the multimerization of nucleophosmin and the biological activity of nucleophosmin, such as the ability of nucleophosmin to inhibit apoptosis and inhibit cellular differentiation. These small molecule inhibitors are useful for treating diseases and disorders, such as cancer associated with dysregulated nucleophosmin expression. Methods for identifying small molecule inhibitors of nucleophosmin involving multimerization sites for nucleophosmin are also disclosed. An exemplary small molecule inhibitor of nucleophosmin is NSC348884 which has the following chemical structure:
REFERENCES:
patent: 5563147 (1996-10-01), Gilmore et al.
patent: 2002/0161022 (2002-10-01), Reich et al.
patent: 2005/0009119 (2005-01-01), Georges et al.
patent: 2007/0037841 (2007-02-01), Nakatani et al.
patent: WO2007/056155 (2005-11-01), None
Bleiberg, British Journal of Cancer, 1998, Cancer Research Campaign, vol. 77, Supplement 4, pp. 1-3.
Williams et. al., Neoplasia, 1999, Stockton Press, vol. 1, No. 2, pp. 170-176.
Romas, Current Medicinal Chemistry, 2006, Bentham Science Publ., vol. 13, pp. 1859-1876.
Johnstone et. al., Cell, 2002, Cell Press, vol. 108, pp. 153-164.
Miller et. al., Cancer and Metastasis Reviews, 2004, Kluwer Acad. Publ., vol. 23, pp. 119-135.
Yang et. al., Polyhedron, 1995, Pergamon, vol. 14, No. 12, pp. 1565-1570.
Wang, Hematology, 2003, American Society for Hematology, pp. 1-13.
Wang et. al., European Journal of Nuclear Medicine, 1995, Springer-Verlag, vol. 22, No. 3, pp. 233-236.
Takeharu Enomoto, et al., “Essential role of the B23/NPM Core Domain in Regulating ARF Binding and B23 Stability”. Journal of Biological Chemistry, vol. 281, No. 27, Jul. 7, 2006, pp. 18463-18472.
Pui K, Chan, “Cross-linkage of Nucleophosmin in Tumor Cells by Nitrogen Mustard”, Cancer Research, Jun. 15, 1989, pp. 3271-3275.
Haridasan V. M. Namboodiri et al., “The Structure and function of Xenopus No38-Core, a Histone Chaperone in the Nucleolus”, Structure, vol. 12, Dec. 2004, pp. 2149-2160.
Chi Wai So. et al., “Dimerization: a versatile switch for oncogenesis”, blood, vol. 104, No. 4, Aug. 15, 2004, pp. 919-922 and cover page.
Mahadevan Daruka
Olenyuk Bogdan
Qi Wenqing
Arizona Board of Regents on Behalf of the University of Arizona
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Pihonak Sarah
Wang Shengjun
LandOfFree
Inhibitors of nucleophosmin (NPM) and methods for inducing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of nucleophosmin (NPM) and methods for inducing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of nucleophosmin (NPM) and methods for inducing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4297519